MDM2 and hydrops fetalis: Placing HF in the context of clinical-stage synthetic MDM2 inhibitors—most notably the Nutlins (e.g., RG7112) and idasanutlin (RG7388), which are in advanced phase trials—reveals both opportunities and limitations [82].